Evidence map›Paper›PMID 40580553›Full record

ArticleNeuro-oncology2025

Trajectory analysis reveals an uncommitted neuroblastic state in MYCN-driven neuroblastoma development.

Shoma Tsubota, Daniel R Carter, Janith A Seneviratne, Haruka Hirose, Teppei Shimamura, Yukie Kashima, Yutaka Suzuki, Koji Tsuda, Glenn M Marshall, Kenji Kadomatsu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shoma TsubotaDepartment of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-8609-6784
Daniel R CarterSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW, Australia.
Janith A SeneviratneChildren's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, UNSW Sydney, Kensington, NSW, Australia.
Haruka HiroseDivision of Systems Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Teppei ShimamuraDivision of Systems Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yukie KashimaDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Yutaka SuzukiDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.ORCID 0000-0003-4852-1879
Koji TsudaDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Glenn M MarshallKids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.
Kenji KadomatsuInstitute for Glyco-core Research, Nagoya, Japan.

Funding

Japan Science and Technology Agency JPMJCR21U2
6 · The paper itself

Abstract

backgroundUnderstanding the factors that determine the spontaneous regression of pre-cancerous lesions is critical to advancing cancer prevention. Neuroblastoma, a pediatric cancer, undergoes spontaneous regression more frequently than other types of cancer.

methodsHere, we analyzed the transcriptomic features of spontaneous regression in pre-cancerous neuroblasts using Th-MYCN mice, an animal model that closely resembles human neuroblastoma. Single-cell transcriptomic analysis of ganglion tissues from Th-MYCN mice was conducted to elucidate the cellular and molecular underpinnings.

resultsTrajectory analysis of pre-cancerous neuroblasts revealed a distinct subtype we designated as "uncommitted" cells, characterized by the expression of neuronal genes, indicative of a semi-differentiated state. Samples with predicted failed tumorigenesis had a greater proportion of these uncommitted cells, hinting at their association with spontaneous regression. In clinical specimens, heightened uncommitted gene expression corresponded with favorable neuroblastomas and an improved prognosis.

conclusionCollectively, the identification of this novel neuroblastoma-related cell subtype and its transcriptomic signature not only enhances our understanding of spontaneous regression mechanisms but also holds potential for therapeutic advancements in treating neuroblastomas.

Indexed as

Biomarkers, TumorNeuroblastomaN-Myc Proto-Oncogene ProteinAnimalsDisease Models, AnimalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiceMice, TransgenicPrognosisSingle-Cell AnalysisTranscriptomeBiomarkers, TumorMYCN protein, humanMYCN protein, mouseN-Myc Proto-Oncogene ProteinneuroblastomascRNA-seqspontaneous regressionTh-MYCN

Identifiers

PMID40580553
PMCPMC12833547

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.